New Releases

Premium

Clarient announced the launch of its new epidermal growth factor receptor mutation test to help physicians select the right treatment for non-small cell lung cancer patients.

The laboratory-developed test analyzes formalin-fixed, paraffin-embedded tissue samples and detects EGFR mutations to help determine which NSCLC patients will respond to tyrosine kinase inhibitor treatments. The RT-PCR assay detects "the most common mutations of the EGFR gene," according to the company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.